MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.vaa.2021.08.003

Медицинская библиотека · Veterinary anaesthesia and analgesia · 2021

Concentrations of vatinoxan and xylazine in plasma, cerebrospinal fluid and brain tissue following intravenous administration in sheep.

Adam Magdy, Lindén Jere, Raekallio Marja, Abu-Shahba Ahmed, Mannerström Bettina, Seppänen-Kaijansinkko Riitta, Meller Anna, Salla Kati

СтатьяRandomized Controlled Trial, VeterinaryПеревод в очереди

Аннотация

OBJECTIVES

To investigate the extent of vatinoxan distribution into sheep brain, and whether vatinoxan influences brain concentrations of xylazine; and to examine the utility of cerebrospinal fluid (CSF) as a surrogate of brain tissue concentrations for vatinoxan and xylazine.

STUDY

DESIGN

Randomised, blinded, experimental study.

ANIMALS: A total of 14 adult female sheep.

METHODS

Sheep were randomly allocated into two equal groups and premedicated with either intravenous (IV) vatinoxan (750 μg kg-1, VX) or saline (SX) administered 10 minutes before IV xylazine (500 μg kg-1). Sedation was subjectively assessed at selected intervals before and after treatments. At 10 minutes after xylazine administration, a venous blood sample was collected and the sheep were immediately euthanised with IV pentobarbital (100 mg kg-1). Plasma, CSF and brain tissues were harvested, and concentrations of vatinoxan and xylazine were quantified using liquid chromatography-tandem mass spectrometry. Drug ratios were then calculated and the data were analysed as appropriate.

RESULTS

The brain-to-plasma and CSF-to-plasma ratios of vatinoxan were 0.06 ± 0.013 and 0.05 ± 0.01 (mean ± standard deviation), respectively. Xylazine brain concentrations were not significantly different (835 ± 262 versus 1029 ± 297 ng g-1 in groups VX and SX, respectively) and were approximately 15-fold higher than those in plasma. The CSF-to-brain ratio of vatinoxan was 0.8 ± 0.2, whereas xylazine concentrations in the brain were approximately 17-fold greater than those in CSF, with and without vatinoxan.

CONCLUSIONS AND CLINICAL RELEVANCE: Vatinoxan did not significantly affect sedation with xylazine or the concentrations of xylazine in the brain. CSF is not a good predictor of xylazine concentrations in the brain, whereas vatinoxan concentrations were concordant between the brain and CSF, using the dosages in this study.

Для цитирования: Adam Magdy, Lindén Jere, Raekallio Marja, Abu-Shahba Ahmed, Mannerström Bettina, Seppänen-Kaijansinkko Riitta, Meller Anna, Salla Kati. Concentrations of vatinoxan and xylazine in plasma, cerebrospinal fluid and brain tissue following intravenous administration in sheep.. Veterinary anaesthesia and analgesia. 2021. DOI: 10.1016/j.vaa.2021.08.003.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.